For more information about MDI's Detect-Ready MRSA assay in Australia, visit: www.integratedsci.com.au/MRSA
About Molecular DetectionMolecular Detection Inc. (MDI), a US-based company with offices in Wayne, PA, Tunbridge Wells, UK and Jerusalem, Israel, is developing and commercializing a portfolio of "sample-to-answer" Detect-Ready™ molecular diagnostic tests for the detection of infectious diseases. The company's first product is a ready-to-use, rapid detection DNA probe test for hospital-based MRSA screening. These staph infections represent a growing problem to the healthcare system. Successful MRSA control efforts rely on screening potential carriers to prevent the spread of the disease. The Detect-Ready MRSA test provides increased accuracy, faster time to results and more efficient utilization of hospital resources compared to other MRSA diagnostic products. It is currently available in the UK, Germany, Ireland, Switzerland, Spain, Austria and Australia, with additional launches expected in the coming months. MDI's real-time PCR tests are based on novel patent-pending technologies for differential diagnosis and room-temperature stabilization. For more information, visit www.detect-ready.com.
About Integrated SciencesEstablished in 1983, Integrated Sciences supplies the Australian Diagnostics and Life Science markets from its offices in Sydney and Melbourne, with direct representation in Brisbane, Canberra, Adelaide and Perth. Integrated Sciences takes pride in offering quality products for life sciences research and clinical diagnostics wi
|SOURCE Molecular Detection Inc.|
Copyright©2010 PR Newswire.
All rights reserved